Pembrolizumab for Marginal Zone Lymphoma

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Marginal Zone Lymphoma+2 MorePembrolizumab - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial studies pembrolizumab as a treatment for B-cell non-Hodgkin lymphoproliferative diseases.

Eligible Conditions
  • Indolent Non-Hodgkin Lymphoma
  • Marginal Zone Lymphoma
  • Follicular Lymphoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Copanlisib
1
Oral Azacitidine
1
Venetoclax

Study Objectives

2 Primary · 8 Secondary · Reporting Duration: Up to 5 years

Year 5
Progression-free Survival
Progression-free survival
Year 5
Duration of Response
Duration of response
Year 5
Time to Next Therapy
Time to next therapy
Day 30
Incidence of adverse events (AEs)
Up to 5 years
Overall response rate (complete response [CR] + partial response [PR] for follicular lymphoma and marginal zone lymphoma)
Up to 8 months.
Overall Response Rate (Complete Response [CR] + Partial Response [PR] for Follicular Lymphoma and Marginal Zone Lymphoma)
Year 1
Count of Participants Who Experience Adverse Events (AEs)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
Copanlisib
1
Oral Azacitidine
1
Venetoclax

Side Effects for

Pembrolizumab Second Course
100%Parkinsonism
100%Urinary tract infection
100%Inappropriate antidiuretic hormone secretion
This histogram enumerates side effects from a completed 2021 Phase 3 trial (NCT03066778) in the Pembrolizumab Second Course ARM group. Side effects include: Parkinsonism with 100%, Urinary tract infection with 100%, Inappropriate antidiuretic hormone secretion with 100%.

Trial Design

1 Treatment Group

Treatment (pembrolizumab)
1 of 1

Experimental Treatment

9 Total Participants · 1 Treatment Group

Primary Treatment: Pembrolizumab · No Placebo Group · Phase 2

Treatment (pembrolizumab)Experimental Group · 2 Interventions: Pembrolizumab, Laboratory Biomarker Analysis · Intervention Types: Biological, Other
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pembrolizumab
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 5 years

Who is running the clinical trial?

Merck Sharp & Dohme LLCIndustry Sponsor
3,673 Previous Clinical Trials
4,958,895 Total Patients Enrolled
University of WashingtonLead Sponsor
1,595 Previous Clinical Trials
1,568,767 Total Patients Enrolled
Ajay K. GopalPrincipal InvestigatorFred Hutch/University of Washington Cancer Consortium
3 Previous Clinical Trials
93 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are willing and able to provide written informed consent/assent for the trial.
You have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) performance scale.
Platelets > 25000/uL if not related to bone marrow involvement.
A lesion is considered to be large if it is greater than 1.5 cm in two dimensions.
You have an indication for treatment.
A participant must be at least 18 years of age and have a neutrophil count of at least 500/uL
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top